Schaub, Christina ; Kebir, Sied ; Junold, Nina ; Hattingen, Elke 
; Schäfer, Niklas ; Steinbach, Joachim P. ; Weyerbrock, Astrid ; Hau, Peter ; Goldbrunner, Roland ; Niessen, Michael ; Mack, Frederic ; Stuplich, Moritz ; Tzaridis, Theophilos ; Bähr, Oliver ; Kortmann, Rolf-Dieter ; Schlegel, Uwe ; Schmidt-Graf, Friederike ; Rohde, Veit ; Braun, Christian ; Hänel, Mathias ; Sabel, Michael ; Gerlach, Rüdiger ; Krex, Dietmar ; Belka, Claus ; Vatter, Hartmut ; Proescholdt, Martin ; Herrlinger, Ulrich ; Glas, Martin
; Schäfer, Niklas ; Steinbach, Joachim P. ; Weyerbrock, Astrid ; Hau, Peter ; Goldbrunner, Roland ; Niessen, Michael ; Mack, Frederic ; Stuplich, Moritz ; Tzaridis, Theophilos ; Bähr, Oliver ; Kortmann, Rolf-Dieter ; Schlegel, Uwe ; Schmidt-Graf, Friederike ; Rohde, Veit ; Braun, Christian ; Hänel, Mathias ; Sabel, Michael ; Gerlach, Rüdiger ; Krex, Dietmar ; Belka, Claus ; Vatter, Hartmut ; Proescholdt, Martin ; Herrlinger, Ulrich ; Glas, Martin 
Abstract
We evaluated patterns of tumor growth in patients with newly diagnosed MGMT-non-methylated glioblastoma who were assigned to undergo radiotherapy in conjunction with bevacizumab/irinotecan (BEV/IRI) or standard temozolomide (TMZ) within the randomized phase II GLARIUS trial. In 142 patients (94 BEV/IRI, 48 TMZ), we reviewed magnetic resonance imaging scans at baseline and first tumor recurrence. ...
Owner only: item control page
Altmetric